Cytos Biotechnology (CSBTF) 3.4900 $CSBTF Allergic

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cytos Biotechnology (CSBTF) 3.4900 $CSBTF

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013
M2 - Thu Feb 20, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/mr7rjr/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013" report to their offering. 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Scope - A snapshot of the global therapeutic scenario for Allergic Rhino-Conjunctivitis. - A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Allergic Rhino-Conjunctivitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Unknown Stage Products Drug Profiles Pollinex Quattro Grass - Drug Profile MK-7243 - Drug Profile MK-3641 - Drug Profile grass pollen allergen extract - Drug Profile Pollinex Quattro Grass - Drug Profile MK-8237 - Drug Profile Grass Pollen Allergoid - Drug Profile Olea Europaea Pollen Extract - Drug Profile Modified Allergen Extract - Drug Profile AL-0704rP - Drug Profile Acaroid - Drug Profile Depigoid Birch - Drug Profile Recombinant Birch Pollen Allergen - Drug Profile Ragweed Pollen Extract - Drug Profile Avanz Phleum Pratense - Drug Profile CYT-003-QbG10 - Drug Profile gpASIT TM - Drug Profile ALK Birch Pollen Vaccine - Drug Profile Osiris - Drug Profile Phleum Pratense - Drug Profile JRC-LAMP Vax - Drug Profile bilastine - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned BioTech Tools ALK-Abello A/S FAES Farma SA Allergy Therapeutics plc Stallergenes S.A. Cytos Biotechnology AG Allergopharma Joachim Ganzer KG Greer Laboratories, Inc. Laboratorios LETI S.L. Immunomic Therapeutics, Inc. Bial - Portela & Ca, S.A. Roxall Medizin GmbH For more information visit http://www.researchandmarkets.com/research/mr7rjr/allergic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Atherosclerosis - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n99vdc/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2013" report to their offering. 'Atherosclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Atherosclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Atherosclerosis. Scope - A snapshot of the global therapeutic scenario for Atherosclerosis. - A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Atherosclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Isis Pharmaceuticals, Inc. Daiichi Sankyo Company, Ltd Merck & Co., Inc. Novartis AG Dong-A Pharmaceutical Co., Ltd. Dr. Reddy's Laboratories Limited Zydus Cadila Healthcare Limited Bayer AG Genfit PROLOR Biotech, Inc. CSL Limited Yuhan Corporation Anagen Therapeutics, Inc. Cytos Biotechnology AG Pronova BioPharma ASA AFFiRiS AG CIMAB S.A. and many more..... For more information visit http://www.researchandmarkets.com/research/n9...osclerosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Allergies - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Allergies
M2 - Mon Sep 02, 12:23PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kfdwp/allergies) has announced the addition of the "Allergies - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Allergies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergies, complete with latest updates, and special features on late-stage and discontinued projects. Allergies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergies. - A review of the Allergies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - ANERGIS SA - Actelion Ltd - ActogeniX NV - Antigen Express, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biomay AG - Biotec Pharmacon ASA - Clarassance, Inc. - Cytos Biotechnology AG - Dainippon Sumitomo Pharma Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune Design Inc. - ImmunoFrontier, Inc. - Immupharma Plc - Indus Biotech Private Limited - IntelGenx Technologies Corp. - Interprotein Corporation - Japan Tobacco Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Novartis AG - Proteo, Inc. - RaQualia Pharma Inc. - SIFI S.p.A - Shionogi & Co., Ltd. - SuppreMol GmbH - ToleroTech Inc. - United Biomedical, Inc. - Vaxine Pty Ltd - Viromed Co., Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/2kfdwp/allergies About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Conjunctivitis - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3z578/conjunctivitis) has announced the addition of the "Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Conjunctivitis. 'Conjunctivitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Conjunctivitis Overview Therapeutics Development An Overview o

Global Allergic Rhino-Conjunctivitis Report - Pipeline Review, H1 2013 Edition
M2 - Thu Jun 06, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vm88b/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2013" report to their offering. 'Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Scope - A snapshot of the global therapeutic scenario for Allergic Rhino-Conjunctivitis. - A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012 Gives a Clear Account of the Market
M2 - Mon Feb 18, 8:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/cdgh58/allergic) has announced the addition of Global Markets Direct's new report "Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Allergic Rhino-Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets D

Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2012 Features Players BioStar Pharmaceuticals, Inc., Yuhan Corporation and Rigel Pharmaceuticals, Inc.
M2 - Fri Dec 21, 10:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/5jdf49/respiratory_tract) has announced the addition of Global Markets Direct's new report "Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Tract Inflammatory Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Inflammatory Disorders. Respiratory Tract Inflammatory Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Highway 99 Truck Death Puts Safety Records in Focus

Updated Category News Views 72

A stopped car on a highway shoulder is supposed to be a bad day, not a death sentence. Yet on November 5, 2026, a person helping a relative with a disabled vehicle was killed on northbound Highway 99 in Elk Grove after a commercial tractor-trailer allegedly drifted onto the shoulder, hit both stationary vehicles, and overturned. Northbound lanes were closed for hours. A...

Continue Reading
Leatt Sets Its Virtual 2026 Shareholder Meeting Date

Updated Category News Views 73

A calendar notice is not a catalyst, but ignoring the calendar is how shareholders miss the small moments that matter. Leatt Corporation has scheduled its 2026 virtual annual general meeting of stockholders for Friday, November 20, at 11:00 AM Eastern Time. For holders of OTCQB:LEAT, this is a basic corporate-governance event, not a new product launch or a financial...

Continue Reading
Roland DG's Brand Refresh Earns Three B2B Awards in 2026

Updated Category News Views 98

Three trophies for a printer-maker’s marketing overhaul will not move mountains by themselves, but they do tell us Roland DG has stopped treating its brand like an afterthought. The company’s global Make Your Mark refresh picked up two Silver awards and one Bronze at the 2026 Drum B2B Awards in Miami. For a business selling industrial-grade tools into crowded,...

Continue Reading
Devicie Broadens Browser Security Across Device Fleets

Updated Category News Views 57

Browsers have quietly become the front door, side door, and occasionally the busted basement window of corporate security. Devicie’s newly expanded Edge for Business Reporting Connector tackles that uncomfortable reality by pulling browser security events from Windows, macOS, iOS, and Android into the same console customers use to oversee Microsoft Intune environments....

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 92

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 77

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 109

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 48

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 96

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
DigiKey’s Arduino Webinar Puts Edge AI Hardware to Work

Updated Category News Views 87

A Small Board With a Big Practical Question Edge AI is finally getting dragged out of the slide deck and onto the workbench, which is where it ought to prove itself. DigiKey plans to host a free 60-minute webinar on Dec. 2, 2026, at 10 a.m. CST covering Arduino’s new VENTUNO Q edge AI computer. The session promises a hardware tour, an Arduino App Lab walkthrough, and a...

Continue Reading

Top 5 Most Recently Viewed Articles

Jordyn Poulter Shines in Times Square After Olympic Success

Updated Category News Views 419

Jordyn Poulter Shines in Times Square After Olympic Success Attention volleyball fans and supporters of women's sports: professional women's volleyball has officially made its mark in the United States. Today, a stunning billboard featuring Olympic silver medalist Jordyn Poulter was unveiled in the bustling Times Square of New York City. Poulter previously played for UYBA...

Continue Reading
Lifecore Biomedical Plans Exciting Financial Update Soon

Updated Category News Views 260

Lifecore Biomedical Prepares to Share Financial Insights Lifecore Biomedical, Inc. (NASDAQ: LFCR) is gearing up to share its financial outcomes for the second quarter of fiscal year 2025 in early January. This exciting announcement marks a significant moment for the company, which is known for its expertise in the contract development and manufacturing landscape. What to...

Continue Reading
Peloton Interactive, Inc. Sets Earnings Call for Q1 of 2025

Updated Category News Views 86

Peloton Interactive, Inc. Earnings Call Announcement Peloton Interactive, Inc. (NASDAQ: PTON) is gearing up for an important announcement regarding its financial results. The company will share its first quarter fiscal 2025 results before the stock market opens on a Thursday in late October. This is a key moment for both the company and its investors, as it lays out the...

Continue Reading
Centerspace Boosts Core FFO Guidance Amid Market Challenges

Updated Category News Views 159

Centerspace's Successful Third Quarter Performance Centerspace (NYSE: CSR), a prominent real estate investment trust, reported a strong third quarter performance in 2024 during its recent earnings call. The company announced a core funds from operations (FFO) of $1.18 per share, reflecting a notable 3% rise in same-store revenue, alongside an improved occupancy rate of...

Continue Reading
Ammunition Depot Crowned as Leading Online Ammo Retailer

Updated Category News Views 277

Ammunition Depot Crowned as Leading Online Ammo Retailer Ammunition Depot has been recognized as the best online destination for purchasing ammunition, according to a recent feature in Guns & Ammo Magazine. This accolade highlights their dedication to delivering a remarkable customer experience complemented by fast shipping and extensive product offerings. In a detailed...

Continue Reading